New work from the @JanewayLab reporting on a pediatric cancer patient cohort sequenced @DanaFarber with 95! different cancer diagnoses. So important to share data to learn about @RareCancer https://t.co/E24bbUE1OB

It is the anniversary of our patient partnered osteosarcoma project — https://t.co/cCaK0hGp7i — creating a clinico-genomic database for the research community to drive discovery. Patients enroll online. Consider referring your patients during #childhoodcancerawareness month

Awesome getting to see Maeve from @JanewayLab and @AgentsMIB present a poster at #ASCO23!

⁦So happy to see work done by Maeve Smart ⁦@JanewayLab⁩ about Covid-19 infection in pediatric cancer patients at #ASCO2023

Excited to present on our patient partnered research on osteosarcoma and leiomyosarcoma next month!!

Join us, @DanaFarber, and @theNCI on May 25 for an informational webinar to hear more about our work in #osteosarcoma (OS) and #leiomyosarcoma (LMS) research. Register at: https://t.co/rrkDWAosKV. @PECGSnetwork #CancerMoonshot #HealthEquity #Oncology #PatientResearch #PECGS

Pediatric Cancer Working Group session #AACR2023 #osteosarcoma @OSInstitute @janeway_MD @huntsmancancer @DanaFarber #MIBagents #MakeItBetter

We are excited to share our recent publication in @JCOPO_ASCO, "FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.” Thank you to all our collaborators and co-authors! https://t.co/VyqB5tAHjY

“All authors have contributed equally to this manuscript”

86% of pediatric cancer patients w extracranial solid tumors have genomic alterations that potentially impact clinical care. Important somatic sequencing results from the GAIN/iCAT2 study.Beautiful work @AlannaChurch_MD @janeway_MD @JanewayLab et al. https://t.co/90JJpGpBnu

A new study published in @NatureMedicine found that 86 percent of extracranial solid tumors in pediatric patients had genomic alterations. Learn more about the findings from lead author Dr. Alanna Church @AlannaChurch_MD in @HealthDayTweets. https://t.co/rqbJ0XFka7.

An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy @janeway_MD @JanewayLab @AlannaChurch_MD https://t.co/SuFi8gr1jN

Getting ready for my presentation 👩‍💼this afternoon at 3p ET. Please join us for this free webinar to get to know @AgentsMIB and to hear about how molecular profiling is helping #ChildhoodCancer The @NatureMedicine paper is available here:

An incredibly gifted writer, a bright soul, and an ARMS warrior, Kasey Altman. Rest in the sweetest peace.

Excited #CCDI Molecular characterization initiative of @COGorg now enrolling #sarcoma! Molecular tumor profiling of enrolled patients @nationwidekids is similar DNA and RNA sequencing as our study just published in @NatureMedicine showing clinical benefit: https://t.co/BslVmPaK7a

This team <3 @JanewayLab @janeway_MD @hycomeau

@notSoJunkDNA @NatureMedicine @janeway_MD @AlyaaIbraheemi @SethPinches @bdcrompton @LauraMacconaill @DFBC_PedCare @DanaFarber @BostonChildrens @SamVolchenboum @JanewayLab All of the data is available in the supplement for the manuscript. The fusions in this cohort are DNAJB1::PRKACA in fibrolamellar carcinoma, an entity beautifully described by @DrSolidTumors here:

@AlannaChurch_MD @NatureMedicine @AlyaaIbraheemi @SethPinches @bdcrompton @LauraMacconaill @DFBC_PedCare @DanaFarber @BostonChildrens @SamVolchenboum @JanewayLab It has been great working with @AlannaChurch_MD , colleagues from 16 institutions, and patients and families on this report from the GAIN consortium/iCat2 study addressing the clinical impact of targeted NGS in pediatric solid tumors. Collaboration is key for rare cancers!

An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy @janeway_MD @JanewayLab, @AlannaChurch_MD https://t.co/SuFi8gr1jN

@NatureMedicine @AlannaChurch_MD @janeway_MD @JanewayLab Congratulations @AlannaChurch_MD, @janeway_MD, and all!